Prostate cancer gene therapy - MayneAlternative Names: FP 253
Latest Information Update: 12 Jan 2006
At a glance
- Originator Symbion Health
- Class Antineoplastics; Gene therapies
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Prostate cancer